Progress Software (PRGS) is to restate its previously issued financial statements in order to correct errors relating to its accounting for stock-based compensation. It does not expect restatement will have any impact on its previously reported revenue.

Genzyme (GENZ) says it plans to initiate a tender offer to acquire AnorMED (AOM) in the form of an all-cash transaction, valuing AnorMED at $8.55 per share. Earlier, AnorMED said its board unanimously rejected Genzyme's $8.55 per share offer.

Taro Pharmaceutical Industries (TARO) is to revise its estimates of accounts receivable reserves for prior years; this will result in restatement of 2003 and 2004 results. The company's independent auditors request that the Audit Committee retain independent counsel to investigate.

Micros Systems (MCRS) posts 53 cents vs. 45 cents fourth quarter GAAP EPS on a 12% revenue rise. It sees $170 million to $173 million first quarter revenue and 33 cents to 36 cents GAAP EPS. It also sees $778 million to $781 million fiscal year 2007 revenue and $1.90-$1.94 EPS.